Avidity Biosciences Partners with Circular Genomics to Advance Alzheimer's Diagnostics

Circular Genomics Relocates to Enhance Alzheimer's Diagnostics Development

Circular Genomics, a pioneer in circular RNA (circRNA) biomarkers, announces its relocation to Lilly Gateway Labs in San Diego, California. This strategic move is designed to foster collaboration with Eli Lilly and Company, enhancing innovation in the development of diagnostics and prognostics for Alzheimer's disease (AD). Paul Sargeant, the CEO of Circular Genomics, highlights that this transition marks a significant opportunity to leverage Lilly’s extensive neuroscience expertise to advance groundbreaking blood tests for AD. The partnership with Alexandria Real Estate Equities, Inc. aims to create a conducive environment for the development of precise diagnostic tools essential for understanding and managing neurodegenerative diseases.

The company has made notable strides in the past, including the launch of its early access program for MindLight™ in September 2024. This innovative test represents the first circRNA biomarker-based blood test capable of predicting patient responses to selective serotonin reuptake inhibitors (SSRIs), a significant advancement in the treatment of major depressive disorder (MDD). Building on this momentum, Circular Genomics is developing additional circRNA assays, including one that accurately identifies patients at high risk for AD progression. By creating precise diagnostic tools, Circular Genomics aims to improve patient stratification, clinical trial candidate selection, and the monitoring of disease progression and treatment efficacy.

The relocation to the Gateway Labs at One Alexandria Square Megacampus is expected to accelerate Circular Genomics’ mission to refine and enhance AD diagnostic and prognostic capabilities. This initiative demonstrates the company's commitment to addressing critical unmet needs in the field of neurodegenerative disease diagnostics. By utilizing clinically validated, brain-derived biomarker assays, Circular Genomics is poised to revolutionize the approach to diagnosing and managing brain disorders, ultimately improving patient care and outcomes in a field where precision is paramount.

In addition to its focus on Alzheimer's diagnostics, Circular Genomics continues to innovate within the realm of mental health. The company's circRNA platform has the potential to transform the landscape of psychiatric care by providing more accurate predictions of treatment responses. This could lead to more personalized treatment plans, significantly impacting patient outcomes in mental health disorders.

Overall, Circular Genomics' strategic relocation and collaboration with Eli Lilly and Alexandria Real Estate Equities represent a pivotal moment in the advancement of neurodegenerative disease diagnostics, setting the stage for transformative developments in patient care and treatment efficacy.